Editor
Medical Technology Stock Letter
John McCamant joined the Medical Technology Stock Letter as associate editor in 1987 and was named editor of this leading investment newsletter in August 2000. He has spent 25 years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, Mr. McCamant uncovered investment opportunities and guided investment strategy. At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, Bloomberg, and Marketwatch.
Biomarin (BMRN) just recently announced that the FDA has accepted for Priority Review the BLA for Va...
We strongly recommend that investors take advantage of the weakness and buy Alkermes (ALKS), explain...
At the recent JPMorgan conference, ACADIA Pharmaceuticals (ACAD) presented a business update highlig...
Nektar Therapeutics (NKTR), is a top pick for 2020, suggests John McCamant, an industry-leading biot...
